




Recovering Hearts. Saving Lives.™


Q4 FY 2019 Earnings Call
Financial Results & Operational Highlights

FINANCIAL RESULTS, Q4 FY 2019


Revenue (\$M) & Growth Rate




Cash (\$M)



Gross Margin %




Operating Margin %




FINANCIAL RESULTS, ANNUALLY


Revenue (\$M) & Growth Rate




Cash (\$M)



Gross Margin %




Operating Margin %




U.S. UTILIZATION MIX, Q4 FY 2019

Revenue by Impella Device




Utilization by Indication



U.S. Revenue Growth:
16%

U.S. Patient Growth:
14%

U.S. Hospital Site Penetration



ABIOMED FY 2020 GUIDANCE

Abiomed FY'20 Guidance

Revenue

\$900M - \$945M ; +17 - 23% YOY

Operating Margin %


29 - 31%

SUMMARY OF RIGHT SIDE SUPPORT DATA


Survival

Longest of 30 day / Discharge / Next Therapy

FDA Approval Studies
(Same In/Exclusion Criteria)



Impella RP
FDA Post-Approval Study




1. Includes patients w/ CPR but excludes in shock >48 hours

Survival

To Transfer or Discharge

Adult Cardiac ECMO²
(Self-Reported Registry Data, No
FDA PMA or Post-Approval Studies)



2. ELSO International Summary January 2019